Currently, multiple myeloma is not yet considered a curable disease. Despite the recent
advances in therapy, the average patient lifespan is still unsatisfactory. Recently, CDK9 …

Currently, multiple myeloma is not yet considered a curable disease. Despite the recent
advances in therapy, the average patient lifespan is still unsatisfactory. Recently, CDK9 …

Introduction: TG02 is an orally-bioavailable, multikinase inhibitor where the primary
mechanism of action is through CDK9-dependent depletion of oncoproteins such as Mcl-1 …

The emergence of new drugs is a major feature of the treatment history of multiple myeloma
(MM), which also reflects the current incurability of MM. As a unique member of cyclin …

Most myeloma patients still experience recurrent relapse and eventually become resistant
and/or intolerant of effective agents such as corticosteroids, alkylating agents, immune …

Multiple myeloma (MM) is a heterogeneous malignancy of plasma cells. Despite
improvement in the prognosis of MM patients after the introduction of many new drugs in the …

* Correspondence to: Ki-Young Lee; Email: kylee@ ucalgary. ca Submitted: 07/30/12;
Accepted: 08/20/12 http://dx. doi. org/10.4161/cc. 21886 investigate the link between the …

Multiple myeloma (MM) ranks second in malignant hematopoietic cancers, and the most
common anti-MM drugs easily generate resistance. CDK4/6 have been validated to play …

Background Despite major advances in multiple myeloma (MM) therapy over the last 2
decades, most patients relapse. The identification of novel targets and development of …

Multiple myeloma (MM) cells are characterized by cell cycle dysregulation, epigenetic
heterogeneity, and perturbation of the transcriptional landscape. We have previously shown …